TransMedics Group, Inc. (NASDAQ:TMDX) Sees Significant Increase in Short Interest

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 11,130,000 shares, an increase of 23.8% from the January 15th total of 8,990,000 shares. Based on an average daily trading volume, of 2,000,000 shares, the short-interest ratio is currently 5.6 days.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 1,084 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares of the company's stock, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 7.00% of the company's stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently added to or reduced their stakes in the business. Atlas Capital Advisors Inc. acquired a new stake in shares of TransMedics Group during the fourth quarter worth $31,000. Hager Investment Management Services LLC acquired a new stake in TransMedics Group during the fourth quarter worth about $33,000. Sachetta LLC acquired a new stake in TransMedics Group during the fourth quarter worth about $40,000. AlphaQuest LLC bought a new position in TransMedics Group in the fourth quarter worth about $52,000. Finally, Quarry LP boosted its stake in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company's stock valued at $58,000 after acquiring an additional 312 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Canaccord Genuity Group decreased their target price on shares of TransMedics Group from $109.00 to $104.00 and set a "buy" rating for the company in a research note on Wednesday, November 20th. Robert W. Baird decreased their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating for the company in a research report on Wednesday, December 11th. TD Cowen dropped their target price on TransMedics Group from $175.00 to $120.00 and set a "buy" rating on the stock in a research report on Monday, November 18th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Wednesday, February 5th. Finally, Oppenheimer restated an "outperform" rating and set a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $122.70.

TransMedics Group Stock Performance

Shares of TMDX traded up $2.84 during mid-day trading on Tuesday, hitting $75.02. The stock had a trading volume of 1,004,733 shares, compared to its average volume of 2,255,254. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company has a market cap of $2.52 billion, a PE ratio of 79.81 and a beta of 2.12. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company's fifty day simple moving average is $65.92 and its two-hundred day simple moving average is $105.97.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.